Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Substudy 06C of an umbrella phase 1/2 trial of investigational agents with pembrolizumab and chemotherapy in first-line advanced gastroesophageal adenocarcinoma
2023-509307-33-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of sacituzumab tirumotecan, MK-1022, pembrolizumab, oxaliplatin, fluorouracil and 3 more in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of participants who experience one or more dose-limiting toxicities, Number of participants who experienced an adverse event and 2 more. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2023-509307-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509307-33-00.